{"text": "TITLE:\n      Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)\nSUMMARY:\n      The purpose of this study is to investigate which combination therapy is more effective in\n      reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive\n      patients: AT1 subtype angiotensin II receptor antagonist/calcium channel blocker or AT1\n      subtype angiotensin II receptor antagonist/low dose diuretic.\nDETAILED DESCRIPTION:\n      Recently, antihypertensive combination therapies have been recommended by various guidelines\n      because of their additive effects. Combination therapies of AT1 subtype angiotensin II\n      receptor antagonist and calcium channel blocker or low dose diuretic have shown\n      pharmacological benefit. However, reduction of cardiovascular events and safety profile of\n      these combination therapies under same level of antihypertensive target have not been\n      investigated yet.\n      In this study, primary objective is to compare two combination therapies when\n      antihypertensive target is 140/90mmHg in elderly hypertensive patients with high\n      cardiovascular risk.\n      Further study details as provided by COLM-Study data center\n      Primary Outcomes: A composite of fatal and non-fatal cardiovascular events: Sudden death\n      (death of endogenous origin within 24 hours after acute onset); Cerebrovascular events (new\n      occurrence or recurrence of a cerebral infarction, cerebral hemorrhage, subarachnoid\n      hemorrhage or transient ischemic attack); Coronary events (new occurrence or recurrence of a\n      myocardial infarction, coronary revascularization[PCI or CABG], hospitalization for angina\n      pectoris, hospitalization for heart failure); Renal dysfunction (doubling of serum\n      creatinine and creatinine \u22652.0 mg/dl, end stage renal disease) Secondary Outcomes: All\n      deaths; Death from cardiovascular events; Effects on glucose metabolism(fasting plasma\n      glucose, postprandial glucose, new onset of diabetes mellitus); Incidence of primary\n      outcomes events; New occurrence of atrial fibrillation; Safety; Proportion of the subjects\n      who withdrew from the allocated treatment\nELIGIBILITY CRITERIA:\n      Inclusion Criteria:\n          -  Outpatients aged 65 years or older, and less than 85 years (at the time of informed\n             consent), regardless of sex\n          -  Systolic blood pressure (SBP) \u2265140 mmHg or diastolic blood pressure (DBP) \u226590 mmHg in\n             a sitting position on two consecutive measurements at clinic during use of 1 or more\n             antihypertensive medications.\n          -  Systolic blood pressure (SBP) \u2265160 mmHg or diastolic blood pressure (DBP) \u2265100 mmHg\n             in a sitting position on two consecutive measurements at clinic without\n             antihypertensive medication.\n          -  Require at least one of the following medical history or risk factors\n          -  Medical history\n               -  Cerebrovascular accident: cerebral infarction, brain hemorrhage, subarachnoid\n                  hemorrhage\uff086 months or more prior to registration\uff09\n               -  Myocardial infarction, coronary revascularization (PCI or CABG) \uff086 months or\n                  more prior to registration\uff09\n               -  Angina pectoris (except for the patients having history of hospitalization\n                  within 6 months prior to registration)\n          -  Risk factors\n               -  Male\n               -  Current diabetes mellitus, fasting glucose \u2265 110mg/dL or postprandial glucose \u2265\n                  140mg/dl\n               -  Hypercholesterolemia (Total cholesterol \u2265 260mg/dL)\n               -  Low HDL cholesterolemia (HDL-C \uff1c40mg/dL)\n               -  Microalbuminuria (albumin/cr \u2265 30mg/gCr) or proteinuria (protein \u2265 1\uff0b)\n               -  Left ventricular hypertrophy (ST-T change in the ECG and SV1\uff0bRV5 \u2265 35mm, or left\n                  ventricular mass index: male \u2265 125 g/m2, female \u2265 110 g/m2)\n        Exclusion Criteria:\n          -  Secondary hypertension or malignant hypertension\n          -  History of cerebrovascular accident (including TIA) or myocardial infarction within 6\n             months before registration\n          -  Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)\n             done within 6 months before registration or scheduled\n          -  History of hospitalization for angina pectoris or heart failure within 6 months\n             before registration\n          -  Severe heart failure (New York Heart Association [NYHA] functional class III or more\n             severe)\n          -  Complications of atrial fibrillation, atrial flutter or severe arrhythmia\n          -  Severe hepatic or renal dysfunction (including current treatment of dialysis or renal\n             dysfunction with serum creatinine \u2265 2.0mg/dL)\n          -  Not appropriate for change to the study drugs from current therapy for concurrent\n             disease including coronary diseases (i.e. calcium channel blockers, diuretics, etc)\n          -  History of serious side effect from study drugs (AT1 subtype angiotensin II receptor\n             antagonist, calcium channel blocker, diuretic)\n          -  Life threatening condition (malignant tumor, etc)\n          -  Not suited to be study subject judged by a study physician\n", "cuis": "C0857121 C0947663 C3811910 C3539181 C3539182 C3539954 C3539955 C3539956 C3539957 C3539959 C3539960 C3539961 C3539962 C3539963 C3539964 C3539965 C3539966 C3539967 C3539968 C3539969 C3539970 C3539971 C3539972 C3539973 C3539974 C3539975 C3539976 C3539977 C3539978 C3539979 C3540026 C3540027 C3540028 C3540030 C3540031 C3540719 C3540720 C3540721 C3540722 C3540723 C3540724 C3540740 C3854036 C0012798 C0550672 C3272283 C4050568 C0947630 C0175556 C1550655 C1578485 C1578486 C2360836 C2360838 C2360840 C1552616 C1706244 C0009429 C0556895 C0947630 C1320716 C0857121 C0947663 C0003364 C0006684 C0872271 C0358701 C0573229 C0003009 C0373546 C0523498 C0003018 C0051863 C0051887 C0051889 C0603886 C3653430 C0242975 C0598695 C0360055 C0003009 C0373546 C0523498 C0003018 C0051863 C0051887 C0051889 C0603886 C0012798 C1550472 C3653430 C0242975 C0598695 C0360055 C0678257 C0033080 C1521941 C0009429 C0556895 C0003364 C0857121 C0162791 C0220845 C0282423 C0003009 C0373546 C0523498 C0003018 C0051863 C0051887 C0051889 C0603886 C3811910 C3539181 C3539182 C3539954 C3539955 C3539956 C3539957 C3539959 C3539960 C3539961 C3539962 C3539963 C3539964 C3539965 C3539966 C3539967 C3539968 C3539969 C3539970 C3539971 C3539972 C3539973 C3539974 C3539975 C3539976 C3539977 C3539978 C3539979 C3540026 C3540027 C3540028 C3540030 C3540031 C3540719 C3540720 C3540721 C3540722 C3540723 C3540724 C3540740 C3854036 C0087111 C0005527 C2717877 C0006684 C0872271 C0358701 C0573229 C0012798 C1550472 C3653430 C0242975 C0598695 C0360055 C1320716 C0441610 C0009429 C0556895 C0003364 C0857121 C0009429 C0556895 C0018017 C2239270 C2979883 C0947630 C0003364 C0857121 C0947663 C3887460 C0007220 C0436125 C0497234 C0947630 C3245479 C1555587 C1320716 C0011071 C1964022 C0439631 C1550512 C0011065 C1306577 C1578513 C0007785 C0393952 C1536121 C0348636 C2937358 C0007784 C0565621 C0472374 C1458156 C2825055 C0003707 C0007787 C0917805 C0019080 C0017181 C1861265 C1458156 C2825055 C1578513 C0018787 C0027051 C2926063 C0155668 C0428953 C0264708 C0155626 C1273976 C0746727 C2348362 C1168331 C0455406 C0340324 C1998297 C0340312 C0340325 C0428950 C2825159 C0019993 C3840878 C3841837 C3841838 C0018787 C0002962 C2024883 C0581603 C0581712 C1565489 C3279454 C0549609 C0019993 C3840878 C3841837 C3841838 C0018801 C0018802 C0229671 C0022661 C2316810 C0854078 C0201975 C1561535 C0027627 C1320716 C0017725 C0011065 C1306577 C0032105 C0011849 C0011878 C0455488 C0743140 C0011860 C1313937 C0746890 C0017725 C0004238 C0344434 C1963067 C2926591 C0340489 C0729790 C1281999 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0243161 C0013893 C0243161 C3843802 C0562357 C0009253 C0428883 C1305849 C0488052 C0277890 C0277889 C0488055 C0871470 C1306620 C1319896 C0277887 C1277633 C2183311 C1282161 C1282162 C1282163 C1282175 C1319894 C2183315 C0802999 C4071678 C0277888 C0428885 C1303019 C1840375 C2133960 C2183314 C4071677 C0277884 C0488231 C1319895 C0488229 C4050449 C0277814 C3166408 C1301304 C0423103 C2048307 C3838520 C0003364 C0857121 C0013227 C2094204 C0802604 C2598133 C2081612 C0033045 C0428883 C1305849 C0488052 C0277890 C0277889 C0488055 C0871470 C1306620 C1319896 C0277887 C1277633 C2183311 C1282161 C1282162 C1282163 C1282175 C1319894 C2183315 C0802999 C4071678 C0277888 C0428885 C1303019 C1840375 C2133960 C2183314 C4071677 C0277884 C0488231 C1319895 C0488229 C4050449 C0277814 C3166408 C1301304 C0423103 C2048307 C3838520 C0003364 C0857121 C0013227 C2081612 C2094204 C0033045 C1971835 C0802604 C2598133 C0262926 C0422836 C0455458 C0455624 C1553898 C4036105 C0455939 C1619636 C0262926 C0422836 C0038454 C0007785 C0393952 C1536121 C0348636 C0553692 C2238497 C0003707 C1553384 C1514821 C1318313 C0019080 C1561542 C0877341 C0027051 C2926063 C0155668 C0455406 C0155626 C0428953 C0948369 C3810814 C3845502 C1561542 C1553384 C1514821 C1318313 C0002962 C0019993 C3840878 C3841837 C3841838 C0262926 C2004062 C0518505 C0522772 C1548746 C1553384 C1514821 C1318313 C1561542 C0455624 C1553898 C2360662 C0011849 C0011878 C0455488 C0743140 C0011860 C1313937 C0015663 C0720371 C0017725 C0020443 C1522133 C0475700 C4015589 C1392499 C0678189 C0201950 C0014487 C1392499 C0151718 C0020443 C1522133 C0151691 C0730345 C1654921 C0201838 C0033687 C1962972 C0853155 C0033621 C1949480 C0038164 C0149721 C3484363 C0232306 C0344398 C0340279 C3476091 C0162770 C0281788 C1845019 C0855329 C0750190 C0455825 C0455860 C0918012 C0770655 C0243161 C0155616 C0155620 C0348586 C0020540 C0024588 C0559159 C4050572 C4062290 C3662044 C3662050 C0027051 C2926063 C0155668 C0428953 C0264708 C0155626 C1273976 C0746727 C2348362 C1168331 C0455406 C0340324 C1998297 C0340312 C0340325 C0428950 C2825159 C1553384 C1514821 C1318313 C1561542 C1532338 C4049682 C4049683 C4034923 C4049680 C4049681 C1532297 C1320647 C4037588 C0010055 C1260596 C0371563 C1961139 C1553384 C1514821 C1318313 C0086960 C1561542 C0019993 C3840878 C3841837 C3841838 C0002962 C0455530 C0018801 C0018802 C0262926 C2004062 C1561542 C1553384 C1514821 C1318313 C0018801 C0018802 C0004083 C0086168 C1547227 C1547231 C1561581 C4050465 C4050466 C0264097 C0018787 C0153500 C0153957 C1281570 C0456387 C0031843 C1306232 C0004238 C0344434 C1963067 C2926591 C0340489 C0729790 C1281999 C0004239 C0344423 C1963068 C0009566 C0802632 C1171258 C2708284 C4032686 C0003811 C0861148 C1306232 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0011946 C1654851 C0205054 C1547227 C1547231 C1561581 C4050465 C4050466 C0264097 C0022646 C0277785 C0201976 C0600061 C0858112 C0428282 C0277785 C0087111 C0033972 C0947630 C0013227 C0006684 C0872271 C0005116 C0010068 C1956346 C0012798 C0012634 C0018609 C0003009 C0373546 C0523498 C0003018 C0051863 C0051887 C0051889 C0603886 C0879626 C0262926 C2004062 C0947630 C0013227 C0700651 C0006684 C0872271 C0358701 C0573229 C0012798 C0381385 C0006826 C0086692 C0496836 C0012634 C3864998 C0009647 C0871117 C0947630 C0804815 ", "concepts": "Hypertensive, Hypertensin, Combination, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, Diuretics, Diuretics Ur, High Risk, High Risk, Study, ccb, Patient, Patient, Patient, Patient, Patient, Patient summary, summary combination therapies, combination therapies, study cardiovascular events, hypertensive, hypertensin, Antihypertensive calcium channel blocker, sodium channel blocker, Atenolol+calcium channel blocker, calcium channel blocker overdose, angiotensin ii, Angiotensin II, Angiotensin I, angiotensin, SMT-angiotensin II, NAB angiotensin II, Br5-angiotensin II, SAMP-angiotensin II, H2-receptor antagonists, GABA receptor antagonist, NMDA receptor antagonist, 5-HT3-receptor antagonist angiotensin ii, Angiotensin II, Angiotensin I, angiotensin, SMT-angiotensin II, NAB angiotensin II, Br5-angiotensin II, SAMP-angiotensin II, diuretic, low, H2-receptor antagonists, GABA receptor antagonist, NMDA receptor antagonist, 5-HT3-receptor antagonist description, prescription, prescription combination therapy, combination therapy, antihypertensive, hypertensive, Guidelines, guidelines, guideline angiotensin ii, Angiotensin II, Angiotensin I, angiotensin, SMT-angiotensin II, NAB angiotensin II, Br5-angiotensin II, SAMP-angiotensin II, Combination, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, therapies, Biotherapies, Apitherapies calcium channel blocker, sodium channel blocker, Atenolol+calcium channel blocker, calcium channel blocker overdose, diuretic, low, H2-receptor antagonists, GABA receptor antagonist, NMDA receptor antagonist, 5-HT3-receptor antagonist cardiovascular events, reduction combination therapy, combination therapy, antihypertensive, hypertensive combination therapy, combination therapy, Objective, objective, Objective, study Antihypertensive, hypertensive, hypertensin cardiovascular, cardiovascular drug, cardiovascular exam, Pain;cardiovascular Study, data, provider cardiovascular events, sudden death, Sudden death, Primary origin, deaths, death, new Cerebral infarction NOS, precerebral infarction, Old cerebral infarction, Other cerebral infarction, intracerebral hemorrhages, Cerebral hemorrhage, Fetal cerebral hemorrhage, Lobar cerebral hemorrhage, recurrence, Recurrence, arachnoid Transient ischemic attack, Transient ischemic attacks, hemorrhage, GI hemorrhage, No hemorrhage, recurrence, Recurrence, new, coronary Myocardial infarction, NOS, Myocardial infarction, Healed myocardial infarction, ECG: myocardial infarction, atrial myocardial infarction, Acute myocardial infarction, First myocardial infarction, septal myocardial infarction, Septal myocardial infarction, Apical myocardial infarction, FH: Myocardial infarction, Silent myocardial infarction, Recent myocardial infarction, Lateral myocardial infarction, Aborted myocardial infarction, ECG: no myocardial infarction, Date of myocardial infarction, hospitalization, Hospitalization 1, Hospitalization 3, Hospitalization 2, coronary, anginas, angina, revascularization, Devascularization Renal dysfunction, Renal dysfunction, adrenal dysfunction, hospitalization, Hospitalization 1, Hospitalization 3, Hospitalization 2, heart failures, Heart failure, serum end-stage renal disease, End stage renal disease, Diabetic end stage renal disease, Creatinine, Creatinine, secondary cardiovascular events, glucose, Death, Death, plasma diabetes mellitus (DM), diabetes mellitus diet, H/O: diabetes mellitus, diabetes mellitus risk, NIDDM diabetes mellitus, FH: Diabetes mellitus, new onset, glucose atrial fibrillation (AF), ECG: atrial fibrillation, Atrial fibrillation, Atrial fibrillation, Lone atrial fibrillation, H/O: atrial fibrillation, Rapid atrial fibrillation Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment criteria, Eligibility Criteria 65 years old or older, Uninformed sex diastolic blood pressure, dbp, Diastolic blood pressure, low diastolic blood pressure, high diastolic blood pressure, Systolic blood pressure, Systolic blood pressure, NOS, sbp, Lying diastolic blood pressure, Diastolic blood pressure normal, Target diastolic blood pressure, diastolic blood pressure at rest, Minimum diastolic blood pressure, Maximum diastolic blood pressure, Average diastolic blood pressure, 24 hour diastolic blood pressure, Sitting diastolic blood pressure, diastolic blood pressure left leg, Diastolic blood pressure by US, Aorta Diastolic blood pressure, Abnormal diastolic blood pressure, Invasive diastolic blood pressure, Standing diastolic blood pressure, Elevated diastolic blood pressure, reported diastolic blood pressure, diastolic blood pressure left arm, Aorta Systolic blood pressure, high systolic blood pressure, Systolic blood pressure--supine, Lying systolic blood pressure, Systolic blood pressure--sitting, Invasive Systolic blood pressure sitting position, Testing position, Fitting point position, Eye measurements, ICD measurements, arm measurements antihypertensive, hypertensive, medications, medications:, Medications, Medications, medication:, Premedications diastolic blood pressure, dbp, Diastolic blood pressure, low diastolic blood pressure, high diastolic blood pressure, Systolic blood pressure, Systolic blood pressure, NOS, sbp, Lying diastolic blood pressure, Diastolic blood pressure normal, Target diastolic blood pressure, diastolic blood pressure at rest, Minimum diastolic blood pressure, Maximum diastolic blood pressure, Average diastolic blood pressure, 24 hour diastolic blood pressure, Sitting diastolic blood pressure, diastolic blood pressure left leg, Diastolic blood pressure by US, Aorta Diastolic blood pressure, Abnormal diastolic blood pressure, Invasive diastolic blood pressure, Standing diastolic blood pressure, Elevated diastolic blood pressure, reported diastolic blood pressure, diastolic blood pressure left arm, Aorta Systolic blood pressure, high systolic blood pressure, Systolic blood pressure--supine, Lying systolic blood pressure, Systolic blood pressure--sitting, Invasive Systolic blood pressure sitting position, Testing position, Fitting point position, Eye measurements, ICD measurements, arm measurements antihypertensive, hypertensive, Medications, medication:, medications:, Premedication, IV medication, Medications, Medications medical history, No medical history, Past medical history, risk factors, risk factors, No risk factors, A/N risk factors, Required Medical history, No medical history Cerebrovascular accident, Cerebral infarction NOS, precerebral infarction, Old cerebral infarction, Other cerebral infarction, brain hemorrhage, brain CT hemorrhage, arachnoid registration, Registration, Jaw registration, hemorrhage, month coronary revascularization, Myocardial infarction, NOS, Myocardial infarction, Old myocardial infarction, FH: Myocardial infarction, Myocardial infarction acute, ECG: myocardial infarction, Myocardial reinfarction, Myocardial Infarction, Myocardial infarction, stroke, month registration, Registration, Jaw registration Angina pectoris, hospitalization, Hospitalization 1, Hospitalization 3, Hospitalization 2, history, history, shaving, shaving, Shaving registration, Registration, Jaw registration, month risk factors, risk factors, Risk factors Doc diabetes mellitus (DM), diabetes mellitus diet, H/O: diabetes mellitus, diabetes mellitus risk, NIDDM diabetes mellitus, FH: Diabetes mellitus, fasting, fastin, glucose Hypercholesterolemia, NOS, Hypercholesterolemia result, FH: Hypercholesterolaemia, Hypercholesterolemia (10%), cholesterolemia, Pure hypercholesterolemia, Cholesterol, Epicholesterol cholesterolemia, Hypocholesterolemia, hypercholesterolemia, Hypercholesterolemia, Low HDL [D]Microalbuminuria, Macroalbuminuria, Microalbumin, proteinurias, Proteinuria, No proteinuria, protein C, protein C, protein a Left ventricular hypertrophy (disorder), Left ventricular hypertrophy, Left ventricular hypertrophy by EKG, ECG: Left ventricular hypertrophy, ventricular hypertrophy, Left ventricular hypertrophy change, Right ventricular hypertrophy, Biventricular hypertrophy, Left ventricular septal hypertrophy, Change in ECG ventricular mass, Left ventricular mass, Right ventricular mass, index, Rindex Criteria Secondary hypertension, Secondary hypertension, benign, Other secondary hypertension, Malignant hypertension NOS, Malignant hypertension History of cerebrovascular accident (situation), History of cerebrovascular accident, History of cerebral vascular accident, History of lacunar cerebrovascular accident, History of parietal cerebrovascular accident, Myocardial infarction, NOS, Myocardial infarction, Healed myocardial infarction, ECG: myocardial infarction, atrial myocardial infarction, Acute myocardial infarction, First myocardial infarction, septal myocardial infarction, Septal myocardial infarction, Apical myocardial infarction, FH: Myocardial infarction, Silent myocardial infarction, Recent myocardial infarction, Lateral myocardial infarction, Aborted myocardial infarction, ECG: no myocardial infarction, Date of myocardial infarction registration, Registration, Jaw registration, month Percutaneous coronary intervention (procedure), Percutaneous coronary intervention panel, Percutaneous coronary intervention panel, Percutaneous coronary intervention report, Percutaneous coronary intervention device panel, Percutaneous coronary intervention device panel, Emergency percutaneous coronary intervention, History of percutaneous coronary intervention, Percutaneous coronary intervention Study report, Coronary artery bypass graft, coronary artery graft bypass, Coronary artery bypass/reop, grafting registration, Registration, Jaw registration, schedule, month hospitalization, Hospitalization 1, Hospitalization 3, Hospitalization 2, angina pectoris, H/O: angina pectoris, heart failures, Heart failure, History, History, month registration, Registration, Jaw registration heart failures, Heart failure, Association, Dissociation, Severe, Severe, Severe, Severe, Severe, Sever, Hearts, Heart, Heart, Heart, class, function severed atrial fibrillation (AF), ECG: atrial fibrillation, Atrial fibrillation, Atrial fibrillation, Lone atrial fibrillation, H/O: atrial fibrillation, Rapid atrial fibrillation, atrial flutter, ECG: atrial flutter, Atrial flutter, complications, Complications, complications, Complications Doc, No Complication, arrhythmia, Proarrhythmia, severed Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, Dialysis, Dialysis, hepatic, Severe, Severe, Severe, Severe, Severe, Sever, renal, Dysfunction serum creatinine test, serum creatinine level, serum creatine, low serum creatinine, Dysfunction therapy, Cotherapy, study, drugs calcium channel blocker, sodium channel blockers, calcium channel blockers bepridil, coronary disease, Coronary disease, diuretics, disease, h disease angiotensin ii, Angiotensin II, Angiotensin I, angiotensin, SMT-angiotensin II, NAB angiotensin II, Br5-angiotensin II, SAMP-angiotensin II, side effect, History, History, study, drugs, Eureceptor calcium channel blocker, sodium channel blocker, Atenolol+calcium channel blocker, calcium channel blocker overdose, diuretic, antagonist G malignant tumor, nonmalignant tumor, eye malignant tumors, condition, Condition, conditioning, precondition study, Physician "}
